GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » EV-to-EBIT

Annovis Bio (Annovis Bio) EV-to-EBIT : -1.32 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Annovis Bio's Enterprise Value is $59.60 Mil. Annovis Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.04 Mil. Therefore, Annovis Bio's EV-to-EBIT for today is -1.32.

The historical rank and industry rank for Annovis Bio's EV-to-EBIT or its related term are showing as below:

ANVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -105.29   Med: 0   Max: 0
Current: -1.32

ANVS's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs ANVS: -1.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Annovis Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $190.97 Mil. Annovis Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.04 Mil. Annovis Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.58%.


Annovis Bio EV-to-EBIT Historical Data

The historical data trend for Annovis Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio EV-to-EBIT Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - -8.00 -6.67 -3.19 -4.24

Annovis Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.19 -3.63 -3.32 -1.87 -4.24

Competitive Comparison of Annovis Bio's EV-to-EBIT

For the Biotechnology subindustry, Annovis Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Annovis Bio's EV-to-EBIT falls into.



Annovis Bio EV-to-EBIT Calculation

Annovis Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=59.603/-45.035
=-1.32

Annovis Bio's current Enterprise Value is $59.60 Mil.
Annovis Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annovis Bio  (NYSE:ANVS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Annovis Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-45.035/190.96713
=-23.58 %

Annovis Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $190.97 Mil.
Annovis Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annovis Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Annovis Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio (Annovis Bio) Business Description

Traded in Other Exchanges
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831